{"id":"cb3b9c42-25d3-589c-97f8-6a573ebed7e4","stable_key":"4d8e4781-3878-5818-8d0a-7dbd6e024555:chromium-biotin-combination-hba1c","predicate":"with_biotin_reduces","statement":"The combination trial reported a between-group difference in HbA1c change (p=0.03); HbA1c fell 0.54 percentage points within the active-treatment group.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"f7a9d7e6-3cdd-53f1-846d-4a1dea34c775","mechanism_event_label":"The two-ingredient treatment improved the average long-term glucose marker, but the contribution of each ingredient is unresolved.","subject":{"id":"89d5d39c-2663-5e0c-8eae-562a5b25a47d","slug":"chromium-iii-picolinate","display_name":"Chromium(III) picolinate / CrPic","entity_type_key":"chemical_species"},"object":{"id":"5deaa98d-e81e-521d-b810-a9228333e4ca","slug":"glycated-hemoglobin-concentration","display_name":"Glycated hemoglobin / HbA1c concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"f7a9d7e6-3cdd-53f1-846d-4a1dea34c775","stable_key":"4d8e4781-3878-5818-8d0a-7dbd6e024555:chromium-biotin-combination-hba1c-event","event_type":"observed_intervention","label":"The two-ingredient treatment improved the average long-term glucose marker, but the contribution of each ingredient is unresolved.","description":"The combination trial reported a between-group difference in HbA1c change (p=0.03); HbA1c fell 0.54 percentage points within the active-treatment group.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"37a8e96b-f95b-5ba7-a0bc-8ed3cfaf5fd8","slug":"biotin","display_name":"Biotin","entity_type_key":"small_molecule"},"role":"co_intervention","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"89d5d39c-2663-5e0c-8eae-562a5b25a47d","slug":"chromium-iii-picolinate","display_name":"Chromium(III) picolinate / CrPic","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"5deaa98d-e81e-521d-b810-a9228333e4ca","slug":"glycated-hemoglobin-concentration","display_name":"Glycated hemoglobin / HbA1c concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/chromium-research/17506119.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126\", \"start_char\": 0, \"end_char\": 1739, \"text_sha256\": \"6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized double-blind placebo-controlled combination trial; 447 enrolled","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"600 µg Cr(III) as picolinate plus 2 mg biotin/day for 90 days with stable oral diabetes medication","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"There were no chromium-only or biotin-only arms. The design cannot identify the active ingredient or prove synergy. Baseline-HbA1c subgroup effects are separately limited.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Chromium research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"chromium","display_name":"Chromium","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Human with poorly controlled type 2 diabetes","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The two-ingredient treatment improved the average long-term glucose marker, but the contribution of each ingredient is unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[chromium-p17506119] Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. (2008). https://pubmed.ncbi.nlm.nih.gov/17506119/ DOI: 10.1002/dmrr.755","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"HbA1c and fasting glucose","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"3384311f-17c7-5d3a-95d6-6e29cc243293","evidence_kind":"source_excerpt","locator":"Lines 692-703","start_line":692,"end_line":703,"excerpt":"### chromium-biotin-combination-hba1c\nThe combination trial reported a between-group difference in HbA1c change (p=0.03); HbA1c fell 0.54 percentage points within the active-treatment group.\nCondition category: normal\nnutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The two-ingredient treatment improved the average long-term glucose marker, but the contribution of each ingredient is unresolved.\norganism: Human with poorly controlled type 2 diabetes\ntissue_or_cell_type: HbA1c and fasting glucose\nexperimental_model: Randomized double-blind placebo-controlled combination trial; 447 enrolled\nlimitations: There were no chromium-only or biotin-only arms. The design cannot identify the active ingredient or prove synergy. Baseline-HbA1c subgroup effects are separately limited.\nexposure: 600 µg Cr(III) as picolinate plus 2 mg biotin/day for 90 days with stable oral diabetes medication\nevidence_span: {\"source_cache\": \"artifacts/chromium-research/17506119.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126\", \"start_char\": 0, \"end_char\": 1739, \"text_sha256\": \"6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126\"}\n[chromium-p17506119] Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. (2008). https://pubmed.ncbi.nlm.nih.gov/17506119/ DOI: 10.1002/dmrr.755","model_system":"Randomized double-blind placebo-controlled combination trial; 447 enrolled","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [chromium-p17506119] Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. (2008). https://pubmed.ncbi.nlm.nih.gov/17506119/ DOI: 10.1002/dmrr.755","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"fa96342a-ca01-5425-98d9-d50e29bf0abd","stable_key":"import-4d8e4781-3878-5818-8d0a-7dbd6e024555","title":"Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"6cae22f9104c6de041b25c23b0fd2884cc57707ac0c9a87c20b0e665d16de5ab","revision_id":"22893798-8329-5295-9c9d-82169032fc79","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}